Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429367 | 0.76 | HDAC1 (0.43) | BRAFRAF1LCKRETPDGFRB | |
| SCHEMBL3219003 | 0.73 | BRAF (0.48) | BRAFKDM4EKMT2AMEN1GAA | |
| SCHEMBL13429357 | 0.70 | AKT1 (0.37) | BRAFRAF1LCKRETPDGFRB | |
| SCHEMBL13429262 | 0.70 | F2 (0.46) | BRAFKDM4EFLT1KDRKMT2A | |
| SCHEMBL13428985 | 0.69 | MEN1 (0.41) | BRAFKDM4ERAF1LCKRET | |
| SCHEMBL13429372 | 0.68 | MEN1 (0.39) | BRAFRAF1LCKRETPDGFRB | |
| SCHEMBL13428999 | 0.68 | CACNA1B (0.50) | BRAFKMT2AMEN1GAA | |
| SCHEMBL13429366 | 0.68 | MEN1 (0.43) | BRAFKDM4EKDRKMT2AMEN1 | |
| SCHEMBL3222479 | 0.68 | MEN1 (0.41) | BRAFRAF1LCKRETPDGFRB | |
| SCHEMBL1666761 | 0.67 | P2RX7 (0.45) | P2RX7PPIAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | P2RX7 1260/4885PPIA 4181/4885BRAF 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.